Actuate Therapeutics Unveils Encouraging Clinical Data for Advanced Salivary Gland Cancers Including Adenoid Cystic Carcinoma

Actuate Therapeutics, Inc. (ACTU) unveiled promising Phase II trial results on Monday, demonstrating the efficacy of elraglusib when combined with standard chemotherapy agents carboplatin or cisplatin in treating advanced metastatic salivary gland cancers. The trial cohort comprised a balanced patient population, with 47% diagnosed with adenoid cystic carcinoma (ACC)—a particularly aggressive salivary gland malignancy—and 53% with other salivary gland cancer subtypes.

The clinical data showed remarkable outcomes across key survival metrics. Patients achieved a median overall survival (OS) of 18.6 months, with substantial portions remaining alive at critical follow-up intervals: 58% at the one-year mark and 40% at two years. Non-adenoid cystic carcinoma patients demonstrated even more impressive survival trajectories, reaching a median OS of 27.8 months.

Progression-free survival (PFS) metrics proved particularly compelling, with a median PFS of 6.4 months observed. Notably, 27% of trial participants maintained progression-free status at one year. This represents a significant departure from historical benchmarks, where adenoid cystic carcinoma patients typically achieved median PFS of approximately 49 months, while non-ACC patients experienced less than 6 months of progression-free survival.

The clinical significance of these findings was validated through publication in Clinical Cancer Research, establishing credibility within the oncology community. The market responded positively to this announcement, with ACTU shares advancing more than 4% during pre-market trading, building on Friday’s close of $7.52 per share, which itself reflected a 1.35% daily gain.

This article reflects factual developments regarding Actuate Therapeutics and does not constitute investment advice or endorsement of any particular investment position.